Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

NCT ID: NCT01819935

Last Updated: 2014-01-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5271 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients meeting inclusion/exclusion criteria from inpatient database from 1/1/02-9/30/10.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

linezolid (Zyvox)

linezolid (Zyvox)

Intervention Type DRUG

As prescribed-this is retrospective cohort of existing clinical data.

Vancomycin

vancomycin

Intervention Type DRUG

As prescribed-this is retrospective cohort of existing clinical data.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

linezolid (Zyvox)

As prescribed-this is retrospective cohort of existing clinical data.

Intervention Type DRUG

vancomycin

As prescribed-this is retrospective cohort of existing clinical data.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MRSA and pneumonia cases by ICD-9 code identification.
* Diagnosis included during inpatient stay.
* Treatment initiation in hospital.

Exclusion Criteria

* Death of discharge within 3 days of treatment initiation.
* Exposure to other treatments with MRSA activity.
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A5951163

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Population Pharmacokinetics of Linezolid
NCT01200654 COMPLETED PHASE4